Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. PEG-interferon alfa-2B may interfere with the growth of cancer
cells. Combining temozolomide with PEG-interferon alfa-2B may be an effective treatment for
advanced solid tumors.
PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and
PEG-interferon alfa-2B in treating patients who have advanced solid tumors.